Advertisement

A pair of Medtronic studies support the Symplicity renal denervation system in treatment of patients with drug-resistant hypertension, with promising results at 1 and 3 years following treatment.

ESC 2013: Medtronic renal denervation going strong at 3 years

New data on Medtronic's (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.

A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.

Advertisement
Advertisement